Studies have shown that the intratumoral injection of the STING agonist developed systemic immune responses in the spleen and tumor-draining lymph nodes, which were indicated by increased levels of IFN-γ-producing CD8+T cells in these organs (73). This evidence concerns the gene STING1 and neoplasm.